B6D2-Tg(KRT5-IKBKB)1Armz/Cnbc

Status

Available to order

EMMA IDEM:09179
International strain nameB6D2-Tg(KRT5-IKBKB)1Armz/Cnbc
Alternative nameB6D2-Tg(krt5-hIKK2)1Armz
Strain typeTransgenic Strains
Allele/Transgene symbolTg(KRT5-IKBKB)1Armz
Gene/Transgene symbolTg(KRT5-IKBKB)1Armz

Information from provider

ProviderAngel Ramirez
Provider affiliationMolecular Oncology Unit, Ciemat
Additional ownerDr. A. Page. Molecular Oncology Unit. CIEMAT. Spain
Genetic informationTransgenic line expressing human IKK2 protein under the regulatory control of elements derived from the bovine Krt5 gene.
Phenotypic informationHomozygous:
Unknown

Heterozygous:
Hemizygous mice have inflammation of oral epithelia (palate and forestomach). Some of the animals (10% - 20%) show squamous cell carcinoma in any of these epithelia that do not progress with age.
Breeding historyThe line has been maintained by crossing the original founder (B6D2F2 background) to B6D2F1 hybrids, for more than 10 generations.
References
  • IKKβ overexpression together with a lack of tumour suppressor genes causes ameloblastic odontomas in mice.;Page Angustias, Bravo Ana, Suarez-Cabrera Cristian, Sanchez-Baltasar Raquel, Oteo Marta, Morcillo Miguel Angel, Casanova M Llanos, Segovia Jose C, Navarro Manuel, Ramirez Angel, ;2020;International journal of oral science;12;1; 31900382
  • IKKβ-Mediated Resistance to Skin Cancer Development Is Ink4a/Arf-Dependent.;Page Angustias, Bravo Ana, Suarez-Cabrera Cristian, Alameda Josefa P, Casanova M Llanos, Lorz Corina, Segrelles Carmen, Segovia José C, Paramio Jesús M, Navarro Manuel, Ramirez Angel, ;2017;Molecular cancer research : MCR;15;1255-1264; 28584022
Homozygous fertilenot known
Homozygous viablenot known
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreCNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain

Disease and phenotype information

MGI allele-associated human disease models

Literature references

  • IKKβ overexpression together with a lack of tumour suppressor genes causes ameloblastic odontomas in mice.;Page Angustias, Bravo Ana, Suarez-Cabrera Cristian, Sanchez-Baltasar Raquel, Oteo Marta, Morcillo Miguel Angel, Casanova M Llanos, Segovia Jose C, Navarro Manuel, Ramirez Angel, ;2020;International journal of oral science;12;1; 31900382
  • IKKβ-Mediated Resistance to Skin Cancer Development Is Ink4a/Arf-Dependent.;Page Angustias, Bravo Ana, Suarez-Cabrera Cristian, Alameda Josefa P, Casanova M Llanos, Lorz Corina, Segrelles Carmen, Segovia José C, Paramio Jesús M, Navarro Manuel, Ramirez Angel, ;2017;Molecular cancer research : MCR;15;1255-1264; 28584022

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).